Emerging Payor Countermeasures To Rare Disease Cost Impact
September 28, 2022
Marwood’s Mark Slomiany addresses the growing orphan drug affordability challenge to payors and emerging countermeasures to mitigate their impact.
CVS Health’s Signify Acquisition Could Increase Congressional, CMS Scrutiny of Risk Adjustment, Diagnosis Codes Collected through HRAs
September 8, 2022
In-home HRAs have seen increased attention over the last year, both in their importance to MA plans, as well as potential regulatory concerns. Marwood’s Joseph Mercer examines policy considerations for deals like CVS Health and Signify Health, in light of Congressional and CMS views on in-home HRAs and potential risk adjustment reform, Medicare trust fund solvency fixes, and increased antitrust activity by FTC and DOJ.
Hub Service Expansion In The Era Of Specialty Drugs
July 6, 2022
Pharma hub services continue to expand with the rise of specialty drugs. Herein, Mark Slomiany addresses their features, transactional trends and regulatory considerations in the patient assistance ecosystem.
The Evolving Telepsychiatry Landscape
June 13, 2022
The burgeoning telepsychiatry space faces rapidly evolving regulatory and competitive dynamics. Marwood Group’s Mark Slomiany examines the market landscape and policy considerations in this behavioral health subsector as the public health emergency draws to an end.
The Resurgence of Independent Pharmacy
May 16, 2022
Independent community pharmacies, once written off, are benefiting from the tailwinds of a post-big box store era. Herein, Marwood’s Mark Slomiany elaborates on how the current landscape benefits nimble independent community pharmacies that not only achieve cost control but diversify their services.
Inflation May Accelerate Trends Reshaping the Healthcare Landscape
March 15, 2022
The recent spike in inflation has yet to fully percolate through the healthcare value chain. Marwood’s Mark Slomiany provides perspective on payor and provider measures and countermeasures likely to accelerate trends reshaping the industry.
2022 Global Pharmaceutical CDMO Outlook
February 14, 2022
In part two of Marwood’s CDMO outlook, Mark Slomiany and Tim Read explore the role CDMOs have played in supporting the pharmaceutical sector, as well as core areas inflecting growth, the evolving M&A landscape, and regulatory considerations.